Radiomic phenotypes in nonmuscle-invasive bladder cancer: A precision biomarker guiding therapy.
Where this comes from
- Record sourced from PubMed, PMID 42558038.
- Also identified by DOI 10.1002/cncr.70563 and PMC identifier 13445133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.